Unity Biotechnology Inc (NASDAQ:UBX) stock has reached a 52-week high, trading at $2.02, signaling a period of robust ...
Sam Altman, the CEO of OpenAI, is backing a groundbreaking initiative aimed at extending human lifespan by a decade through ...
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry ...
Unity Biotechnology Inc’s profitability metrics reveal financial health. The company currently boasts a gross margin of 76.03%. The profit margin, also known as the revenue ratio or gross profit ratio ...
Fintel reports that on January 10, 2025, Chardan Capital initiated coverage of Unity Biotechnology (NasdaqGS:UBX) with a Buy ...
UNITY Biotechnology has appointed Federico Grossi, M.D., Ph.D., as its new chief medical officer to enhance its leadership team. Dr. Grossi, who has over 20 years of experience in biotech ...
SAN FRANCISCO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging ...
Unity Biotechnology, Inc. operates as a biotechnology company. The firm is developing a portfolio of programs like biological mechanisms implicated in diseases of aging, and also senolytic ...
Sam Altman-backed Retro Biosciences is raising $1 billion to develop drugs that extend human lifespan by 10 years, the FT ...